GW Henssler & Associates Ltd. boosted its stake in shares of Mednax Inc. (NYSE:MD) by 4.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,378 shares of the company’s stock after buying an additional 6,171 shares during the period. GW Henssler & Associates Ltd.’s holdings in Mednax were worth $10,385,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. First Quadrant L P CA purchased a new stake in shares of Mednax during the second quarter valued at $130,000. Morgan Dempsey Capital Management LLC raised its position in Mednax by 147.7% in the second quarter. Morgan Dempsey Capital Management LLC now owns 2,192 shares of the company’s stock valued at $159,000 after buying an additional 1,307 shares during the period. Middleton & Co Inc MA bought a new position in Mednax during the second quarter valued at approximately $221,000. JFS Wealth Advisors LLC bought a new position in Mednax during the second quarter valued at approximately $232,000. Finally, P.R. Herzig & Co. Inc. bought a new position in Mednax during the second quarter valued at approximately $239,000. 97.75% of the stock is owned by hedge funds and other institutional investors.
Shares of Mednax Inc. (NYSE:MD) traded down 0.98% during trading on Friday, hitting $65.51. The stock had a trading volume of 482,563 shares. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of 18.28 and a beta of 0.54. Mednax Inc. has a one year low of $61.40 and a one year high of $83.19. The stock’s 50-day moving average price is $65.73 and its 200 day moving average price is $68.32.
Mednax (NYSE:MD) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.07 by $0.04. The company had revenue of $772 million for the quarter, compared to analyst estimates of $775.68 million. Mednax had a return on equity of 14.88% and a net margin of 11.17%. Mednax’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 earnings per share. On average, equities analysts forecast that Mednax Inc. will post $4.14 EPS for the current year.
MD has been the subject of several recent research reports. Zacks Investment Research raised Mednax from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a report on Wednesday, June 29th. Mizuho reaffirmed a “buy” rating and set a $79.00 target price on shares of Mednax in a report on Tuesday, September 20th. Jefferies Group lowered their target price on Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a report on Friday, August 26th. Citigroup Inc. lowered their target price on Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 17th. Finally, JPMorgan Chase & Co. lowered their target price on Mednax from $85.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $76.11.
In related news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the transaction, the director now directly owns 12,755 shares in the company, valued at approximately $829,202.55. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 2.40% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax Inc. (NYSE:MD).
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.